Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Lateral Canthal Lines
NCT03839693Phase 2Completed
- Sponsor
- Eirion Therapeutics
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ET-01 in lateral canthal rhytides, sponsored by Eirion Therapeutics. Started Oct 2018; status: completed.
02
Drugs
ET-01
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT03839693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839693.